Clinical Trial Update: Fostamatinib for the Treatment of Lower-risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia Who Have Failed Therapy With Hypomethylating Agents [Phase 1]

View source ↗

Summary

Phase 1 trial of fostamatinib for lower-risk myelodysplastic syndromes or chronic myelomonocytic leukemia after failure of hypomethylating agents has completed,…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndromes
• Myelomonocytic Leukemia

Drugs mentioned

• Fostamatinib (fostamatinib)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Refractory Chronic Myelomonocytic Leukemia, Refractory Myelodysplastic Syndrome | Phase 1 | Status: COMPLETED